EMA grants rapid reviews for two new myeloma drugs
This article was originally published in Scrip
The European Medicines Agency is to review two novel therapies for multiple myeloma under its accelerated assessment procedure in an effort to get the drugs to market as soon as possible.
You may also be interested in...
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.
A “powerful new vision” for the post-Brexit UK regulatory framework was unveiled at a conference organized by the BioIndustry Association and the medicines regulator, the MHRA.
InflaRx and Relief Therapeutics/NeuroRx are investigating potential new treatments for COVID-19-induced pneumonia and for coronavirus-related ARDS.